Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study

Open access
Hescot, Segolene, Curras-Freixes, Maria, Deutschbein, Timo, van Berkel, Anouk, Vezzosi, Delphine, Amar, Laurence, de la Fouchardière, Christelle, Valdes, Nuria, Riccardi, Fernando, Do Cao, Christine, Bertherat, Jerome, Goichot, Bernard, Beuschlein, Felix, Drui, Delphine, Canu, Letizia, Niccoli, Patricia, Laboureau, Sandrine, Tabarin, Antoine, Leboulleux, Sophie, Calsina, Bruna, Libé, Rossella, Faggiano, Antongiulio, Schlumberger, Martin, Borson-Chazot, Francoise, Mannelli, Massimo, Gimenez-Roqueplo, Anne-Paule, Caron, Philippe, Timmers, Henri J L M, Fassnacht, Martin, Robledo, Mercedes, Borget, Isabelle, Baudin, Eric, European Network for the Study of Adrenal Tumors (ENS@T) · 2019 · The Journal of Clinical Endocrinology & Metabolism

Abstract

BACKGROUND: Malignant pheochromocytoma and paraganglioma (MPP) are characterized by prognostic heterogeneity. Our objective was to look for prognostic parameters of overall survival (OS) in MPP patients. PATIENTS AND METHODS: Retrospective multicenter study of MPP characterized by a neck-thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers between 1998 and 2010. RESULTS: One hundred sixty-nine patients from 18 European centers were included. Main characteristics of patients with MPP were: primary pheochromocytoma in 53% of patients; tumor- or hormone-related symptoms in 57% or 58% of cases; positive plasma or urine hormones in 81% of patients; identification of a mutation in SDHB in 42% of cases. Metastatic sites included bone (64%), lymph node (40%), lung (29%), and liver (26%); mean time between initial and malignancy diagnosis was 43 months (range, 0 to 614). Median follow-up was 68 months and median survival 6.7 years. Using univariate analysis, better survival was associated with head and neck paraganglioma, age <40 years, metanephrines less than fivefold the upper limits of the normal range, and low proliferative index. In multivariate analysis, hypersecretion [hazard ratio 3.02 (1.65 to 5.55); P = 0.0004] was identified as an independent significant prognostic factor of worst OS. CONCLUSIONS: Our results do not confirm SDHB mutations as a major prognostic parameter in MPP and suggest additional key molecular events involved in MPP tumor progression. Aside from SDHB mutation, the biology of aggressive MPP remains to be understood.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-01968

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Hescot, S., Curras-Freixes, M., Deutschbein, T., van Berkel, A., Vezzosi, D., Amar, L., de la Fouchardière, C., Valdes, N., Riccardi, F., Do Cao, C., Bertherat, J., Goichot, B., Beuschlein, F., Drui, D., Canu, L., Niccoli, P., Laboureau, S., Tabarin, A., Leboulleux, S., Calsina, B., Libé, R., Faggiano, A., Schlumberger, M., Borson-Chazot, F., Mannelli, M., Gimenez-Roqueplo, A.-P., Caron, P., Timmers, H. J. L. M., Fassnacht, M., Robledo, M., Borget, I., Baudin, E., & European Network for the Study of Adrenal Tumors (ENS@T)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-02-01
Volume
104
Issue
6
Pages
2367-2374
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2912667865
Cited by
188
References
1
FWCI
19.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. https://app.cochat.ai/papers/10.1210/jc.2018-01968
The paper
Hescot, S., Curras-Freixes, M., Deutschbein, T., van Berkel, A., Vezzosi, D., Amar, L., de la Fouchardière, C., Valdes, N., Riccardi, F., Do Cao, C., Bertherat, J., Goichot, B., Beuschlein, F., Drui, D., Canu, L., Niccoli, P., Laboureau, S., Tabarin, A., Leboulleux, S., . . . European Network for the Study of Adrenal Tumors (ENS@T). (2019). Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-01968

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.